Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Trimmed by Alliancebernstein L.P.

Alliancebernstein L.P. lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,068,432 shares of the biopharmaceutical company’s stock after selling 339,909 shares during the period. Alliancebernstein L.P.’s holdings in Halozyme Therapeutics were worth $146,702,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HALO. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth $29,000. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter valued at $29,000. Smartleaf Asset Management LLC raised its holdings in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 322 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now directly owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,200 shares of company stock worth $1,786,668 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Benchmark reaffirmed a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $61.87 on Wednesday. The stock has a market cap of $7.64 billion, a P/E ratio of 18.04, a P/E/G ratio of 0.42 and a beta of 1.32. The firm’s 50-day simple moving average is $59.34 and its 200 day simple moving average is $54.84. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.